Montaz

# Montaz ## Overview - **Classification**: Second-generation Antihistamine, Non-sedating - **Mechanism**: Selective peripheral H1-receptor antagonist. Blocks histamine release, reducing allergic symptoms like itching, sneezing, and watery eyes. ## Primary Indications 1. **Seasonal Allergic Rhinitis**: Symptomatic relief of sneezing, rhinorrhea, nasal pruritus, ocular pruritus. 2. **Perennial Allergic Rhinitis**: Symptomatic relief of chronic nasal and ocular allergy symptoms. 3. **Chronic Idiopathic Urticaria**: Symptomatic relief of pruritus and reduction in the number and size of hives. ## Adult Dosing ### Standard Dosing **Seasonal & Perennial Allergic Rhinitis, Chronic Idiopathic Urticaria** - **Dose**: **5 mg** - **Frequency**: Once daily - **Route**: Oral - **Duration**: As needed for symptom control ### Dose Adjustments - **Renal Impairment**: * CrCl 30-50 mL/min: **5 mg** every other day * CrCl <30 mL/min: **5 mg** twice weekly * Hemodialysis: Not recommended. - **Hepatic Impairment**: No specific adjustment needed for mild-moderate. Use caution in severe. - **Elderly Patients**: Consider **2.5 mg** daily initially due to potential renal decline. ## Pediatric Dosing ### Neonates (0-28 days) - **Not Recommended**: Safety and efficacy not established. Avoid use. ### Infants (1-12 months) - **Indication**: Allergic Rhinitis, Chronic Idiopathic Urticaria - **Dose**: **1.25 mg** (2.5 mL oral solution) - **Frequency**: Once daily - **Maximum**: **1.25 mg/day** - **Special Notes**: Use oral solution for accurate dosing. Monitor for sedation. ### Children (1-12 years) - **Indication**: Allergic Rhinitis, Chronic Idiopathic Urticaria - **1-5 years**: * **Dose**: **1.25 mg** (2.5 mL oral solution) * **Frequency**: Once daily * **Maximum**: **1.25 mg/day** - **6-12 years**: * **Dose**: **2.5 mg** (5 mL oral solution or half 5mg tablet) * **Frequency**: Once daily * **Maximum**: **2.5 mg/day** ### Adolescents (13-18 years) - **Indication**: Allergic Rhinitis, Chronic Idiopathic Urticaria - **Dose**: **5 mg** - **Frequency**: Once daily - **Maximum**: **5 mg/day** (approaches adult dose) ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to Montaz, hydroxyzine, or piperazine derivatives. - **Absolute**: End-stage renal disease (CrCl <10 mL/min) or hemodialysis. - **Relative**: Severe pre-existing renal impairment (CrCl <30 mL/min); requires dose adjustment. ### Common Adverse Effects - **Very Common (>10%)**: Somnolence/Drowsiness, Headache - **Common (1-10%)**: Dry mouth, Fatigue, Nasopharyngitis, Dizziness - **Serious but Rare**: Hypersensitivity reactions (angioedema, anaphylaxis), Seizures, Hepatic dysfunction. ### Key Drug Interactions - **CNS Depressants (e.g., Alcohol, Sedatives)**: Increased risk of additive CNS depression. Avoid concomitant use. - **Ritonavir**: May increase Montaz plasma levels. Monitor for increased side effects. - **Theophylline**: Minor decrease in Montaz clearance; usually not clinically significant. ## Monitoring & Follow-up - **Before Treatment**: No specific baseline lab tests required. Assess renal function if indicated. - **During Treatment**: Monitor for symptom control and adverse effects, especially sedation. - **Clinical Signs**: Watch for excessive drowsiness, dizziness, or paradoxical excitation (children). ## Clinical Pearls - 💡 **Tip 1**: Can be taken with or without food. - 💡 **Tip 2**: If drowsiness occurs, consider taking the dose in the evening. - 💡 **Tip 3**: Advise patients to avoid alcohol and other CNS depressants due to additive effects. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.